DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Suneva Medical-Viveon Health merger update; Smith+Nephew acquires Engage Surgical; Abiomed's preCARDIA technology; Medtronic’s DTM Spinal Cord Stimulation; Endo Tools Therapeutics’s Endomina System; Diadem's AlzoSure predict prognostic blood test Visit Post
2 Algernon’s NP-120 (ifenprodil); Pieris's cinrebafusp alfa (PRS-343) clinical trial; Gaumard Scientific’s multidisciplinary patient simulator HAL S5301; Hekka Labs’s decentralized healthcare ecosystem Visit Post
3 Leman Micro Devices’ e-Checkup system; Calon Cardio-Technology & Leviticus-Cardio announced Breakthrough; Alcon buys Ivantis; Medtronic to acquire Affera; Abiomed’s Impella 5.5 with SmartAssist; Abbott’s EnSite X EP System with EnSite OT Visit Post
4 Noxxon’s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent’s clinical trails for NVL-520; Stryker acquires Vocera Communications Visit Post
5 Siemens Healthineers’s COVID-19 Antigen Self-Test; Paragon’s R3ACT Stabilization System; Pulnovo Medical’s PADN-CFDA trial; Endotronix’s PROACTIVE-HF trial; Abbott’s Proclaim XR SCS System; RTI Surgical spins off businesses Visit Post
6 Accutar's Phase I clinical trial for AC0176; Bio-Thera's cancer drug, BAT6005; Nykode's Covid-19 vaccine trial; Heat Biologics acquires Elusys Visit Post
7 Cerner, Scanwell Health and Personal Genome Diagnostics Acquisition; Zynex's Fluid Monitoring System, CM-1500; Sight Sciences' TearCare System; Envista's Nobel Biocare N1 Implant System Visit Post
8 Biogen-Eisai's Aduhelm; Quidel acquires Ortho Clinical Diagnostics; Accutar Biotechnology’s AC0176; Boehringer’s Spesolimab Visit Post
9 Sky Medical’s Geko™ device; Fist Assist Devices obtains Breakthrough Device designation; Edwards obtains FDA approval; BD launched instrument for testing; GE acquires BK Medical; Zynex’ CM-1500; Foldax’s TRIA biopolymer heart valve Visit Post
10 Edwards’ Sapien 3 with Alterra Prestent; Koios Medical’s breast, thyroid cancer-spotting AI; Lineage Collaborates with Genentech; Novartis, BeiGene ink deal Visit Post
11 BrainQ's EMAGINE Trial; AtaCor's EV-ICD study; Urotronic's Optilume Urethral Drug-Coated Balloon approval; Medtronic receives 510(k) clearance; Baxter acquires Hillrom Visit Post
12 Boston Scientific's MODULAR CRM System; Restore Medical's ContraBand clinical trial result; BD acquires Venclose; Roche differentiates mutations in Omicron; Linus's StrandDx-ASD; HelioLiver launches liquid biopsy test Visit Post
13 Aslan Pharma - IQVIA collaboration; Reata's kidney drug bardoxolone; Alzheimer’s Disease treatment update; Recordati to acquire EUSA Visit Post
14 LensGen’s Juvene Intraocular Lens; Nevro announces clinical data publications; FDA Clearance to Immunexpress’s SeptiCyte; GE unveils AI and Digital Technologies; Canon launches PIQE DLR and SilverBeam; Hyperfine’s Swoop gets FDA clearance Visit Post
15 GE Healthcare-Optellum's collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel's Mammoscreen Visit Post
16 Neurent Medical’s NEUROMARK; Brain Navi NaoTrac received European CE Mark approval; Theradaptive receives Breakthrough Medical Device Designation; HAGAR GWave awarded Breakthrough Device Designation; Fujifilm launches ColoAssist PRO Visit Post
17 Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M Visit Post
18 Abbott's Pacemaker System; Ivantis’s Hydrus Microstent; Medtronic’s PillCam Small Bowel 3; ALung Technologies's Hemolung; AppliedVR’s EaseVRx; J&J to split into two companies; OrthAlign’s Lantern® launch; LumiThera’s Light-based Theranostic Visit Post
19 AstraZeneca-Moderna's AZD8601 VEGF-A mRNA Trial; Wision AI gets CE Mark approval; Getinge acquires Verrix; LumiThera buys Diopsys Visit Post
20 TecTraum’s pro2cool receives Breakthrough Device Designation; Vektor Obtains FDA Clearance for vMap; Medtronic’s TMVR system; Sight Sciences's PRECISION Trial; Alcon to buy Ivantis; Philips to acquire Cardiologs Visit Post
21 Alcon to acquire Ivantis; Philips to takeover Cardiologs; Flunked cancer drug progresses in I-O in pancreatic cancer models; Indigo system CAT RX catheter meets primary endpoint in trial Visit Post
22 Smith+Nephew's LEGION CONCELOC; Renew Bioscience's Cerezen; Perimeter Medical's ATLAS AI Project; SAGA Diagnostics-AZ's Deal; Magnus Receives Breakthrough Device Designation; ReValve's Transeptal Mitral Valve Replacement Visit Post
23 Magnus Medical’s tech gets breakthrough status; Prolacta develops tests for pathogens detection; Renovia gets breakthrough designation for leva system; Hinge Health secures $600M funding Visit Post
24 FDA 510k clearance to Naviswiss's Naviplan; FDA approved to TYRVAYA; Centinel Spine's STALIF Integrated Interbody System; Smith+Nephew's IODOSORB; AlloSource's AlloMend Extra-Large ADM; SpinaFX and StarFish's strategic commercialisation contract Visit Post
25 Ocular Therapeutix’s insert fails in phase 2; Click Therapeutics raises $52M funding; Roche introduces AVENIO Tumour Tissue CGP Kit; Blue Wolf Capital to acquire CIVCO Radiotherapy Visit Post
26 Hologic to acquire Bolder Surgical; Breakthrough Device Designation to Biological Dynamics; Luminopia declares FDA approval; HistoSonics secures Breakthrough Device Designation; Phillips-Medisize expands worldwide; PolyNovo launches NovoSorb BTM tech Visit Post
27 Biogen's ALS drug Tofersen (BIIB067); Phathom's erosive esophagitis drug trial; Vertex's islet cell therapy; Natera launches lung DNA test Visit Post
28 Bausch + Lomb's LuxSmart Intraocular Lenses; Movair's Luisa Life Supporting Ventilator; Cochlear's Nucleus and Baha Systems; Laborie Acquires Pelvalon; Know Labs's SARS-CoV-2 Research; Syntellix's MAGNEZIX; Visit Post
29 Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS' Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030 Visit Post
30 Amber Implants VCFix spinal system; iotaMotion's iotaSOFT Insertion System; Boston Scientific acquires Baylis; ReCor's Paradise Ultrasound Renal Denervation; Boston Scientific's Ranger Drug-Coated Balloon; Natera's Prospera Visit Post
31 Pfizer tightens DMD trial criteria over safety concerns; Kytopen raises $30M; Eli Lilly taps Reify's Care Access; Vensana Capital raises $325M Visit Post
32 RETINA-AI Health declares positive results; Medtronic's Hugo robotic-assisted surgery system; Boston Scientific acquires Devoro Medical; Paige obtains first-ever FDA approval Visit Post
33 UNION Therapeutics-Innovent's collaboration; Delix Therapeutics bags $ 70 M; Biohaven’s Verdiperstat clinical trial result; Intra-Cellular's CAPLYTA Phase III study Visit Post
34 Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical Visit Post
35 Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain Visit Post
36 FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Visit Post
37 ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System Visit Post
38 Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm Visit Post
39 Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ's HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune's Alzheimer's Antibody Drug Visit Post
40 Abiomed’s Impella ECP; Helius’s PoNS Device; Smart Meter’s iGlucose BGM; XACT’s CT-Guided Percutaneous Procedures; BD’s Veritor At-Home COVID-19 Test; Delfi’s Liquid Biopsy Visit Post
41 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
42 Shape Therapeutics-Roche's Deal; AllStripes Raises $50M; Datavant-Real Chemistry's Partnership; BlueWillow's Nasal Vaccine Visit Post
43 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
44 Boston Scientific’s EkoSonic; FDA clearance for EXALT; Kestra Medical’s ASSURE; ZOLL Next-Generation remedē system; CytoSorbents' DrugSorb-ATR; Fujifilm-Lunit collaboration Visit Post
45 FDA approval to Keytruda and Lenvima; FibroGen's Roxadustat; Pfizer’s TICOVAC; Ipsen’s Palovarotene; Jazz Pharma’s Xywav; Seagen-RemeGen’s Cancer Medicine Visit Post
46 LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drug; Visus raises $20M Visit Post
47 Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea's Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer Visit Post
48 Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion; Mestag with $45M seed; Moderna secures fast track designation Visit Post
49 Nevro's Spinal Cord Stimulation; Boston's PINNACLE FLX; NuVasive's Modulus ALIF; J&J's VERITAS Vision System; Medtronic's DCB Catheter; AngelMed's Heart Attack Warning System Visit Post
50 Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis’ drug meets a goal; AbbVie hits go on $1B re-upped Calico deal Visit Post
51 Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial Visit Post
52 Fight Against the Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market Visit Post
53 BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Visit Post
54 MedTech Wrap Up Visit Post
55 Hepion aces mid-stage study; Bicycle Therapeutics-Ionis collaboration; Nimbus raises $105M; Regeneron to support ISA Pharma Visit Post
56 Bayer's CKD Drug; Enochian’s RNA Hijack for HBV; Novo Nordisk's to get Prothena's ATTR Amyloidosis Business; J&J’s COVID-19 Vaccine Struggle Visit Post
57 Unity's advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka's candidate; Lilly invests in MiNA; Visit Post
58 Arrowhead's ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics's Cell & Gene Therapy; Sirnaomics Secures $105 Million Visit Post
59 MedTech Market Industry: Approval of Devices, Therapy Address Market Needs | Clinical Outcomes Create New Value Visit Post
60 Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future Visit Post
61 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
62 Horizon/ Arrowhead Deal; Dr Reddy's Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill's Oral Opaganib in COVID-19 Visit Post
63 Age-related Hearing Loss Device Market Dynamics Expected to Step into Growth Quadrant Visit Post
64 Eclipse, Medtronic, Aethlon, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward Visit Post
65 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
66 Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird's Gene Therapy Visit Post
67 Latest Medtech Commercial, Regulatory and Clinical Updates For - Abbott, BD, CooperVision, Procyrion, TricValve, and others Visit Post
68 Amgen a leader in Undruggable Lung Cancer; Verrica's Skin Disease Drug Delays; Fennec's Faith in its Chemotherapy-Induced Hearing Loss Drug; Nexturn Bio's Acquisition of RosVivo Visit Post
69 Pieris-Genentech deal; Xilio inks deal with Merck; BMS taps Xencor's tech; GenSight's gene therapy reports partial recovery Visit Post
70 TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug Visit Post
71 MedTech Industry: Commercial, Regulatory and Clinical Updates Visit Post
72 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
73 Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids Visit Post
74 Abingworth & Alebund's Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal Visit Post
75 Pfizer hit by DMD delay & halts BCMA trials; Sarepta's drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic Visit Post
76 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
77 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
78 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
79 Adagio Raises $336 M; Lyndra's Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy Visit Post
80 Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO Visit Post
81 Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities Visit Post
82 Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M Visit Post
83 Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application Visit Post
84 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
85 Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer's Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing Visit Post
86 Asher Bio raises $55M; Roche halts Huntington's phase 3 trial; Novartis' radioligand hits goal in phase 3; EpimAb raises $120M in Series C Visit Post
87 Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC Visit Post
88 GBT strikes a deal with Sanofi; Lilly's IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy Visit Post
89 Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa Visit Post
90 Valo Health receives $110M Series B Cognito's therapy slows Alzheimer's disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio Visit Post
91 Overwhelming success of Gilead/Kite's Yescarta; Ridgeback/ Merck in the COVID-19 game; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer Visit Post
92 Novavax targets COVID-19 approval; Iktos collaborates with Pfizer; AbbVie bags option to acquire Mitokinin; Presage inks new pact with Merck Visit Post
93 Evotec, Chinook Teams Up for CKD Therapy; HitGen & UPPTHERA in Drug Delivery Research; Artiva's $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China Visit Post
94 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
95 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
96 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
97 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
98 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
99 Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials Visit Post
100 Aurinia's Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics’ Financing; Merck’s Covid-19 Vaccine Program End Visit Post
101 Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline. Visit Post
102 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
103 Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate Visit Post
104 Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off Visit Post
105 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
106 Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results Visit Post
107 Improving cancer immunotherapy; Senseonics' Eversense delayed; FDA acknowledges Alkermes' Resubmission; 3D breast ultrasound improves diagnosis Visit Post
108 A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica Visit Post
109 NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche's bispecific matches Eylea; Research Updates in Leukemia, solid tumors Visit Post
110 Agios' cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial Visit Post
111 Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders Visit Post
112 FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel Visit Post
113 AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra's X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Visit Post
114 KaliVir, Astellas licensing deal; AbCellera's IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH Visit Post
115 Roche's quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study Visit Post
116 BASE10 Collaboration; Advaxis Public offerings; Takeda's CABOMETYX Japan approval; TheraPharm Acquisition Visit Post
117 Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant's vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic Visit Post
118 Novartis' COVID-19 deal; Shattered hopes for Remdesivir; Lilly's R&D pact with Precision; Innovent's Humira Biosimilar Visit Post
119 Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M Visit Post
120 Albireo Pharma's PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna's Weapon Against COVID; Gilead & Novo Nordisk's Cocktail Therapy for NASH Visit Post
121 FDA authorizes first diagnostic test for Covid-19 antibodies; EGenesis's collaboration with Duke; Pancreatic Cancer research updates; Decibel scores $ 82 M Visit Post
122 Pfizer's COVID-19 Vaccine; Calliditas' NefIgArd trial; ViiV's HIV Prevention Treatment; Biogen’s Aducanumab Rejection Visit Post
123 Fosun-BioNTech's COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD Visit Post
124 Bristol Myers' psoriasis drug; GW Pharmaceuticals eyes US market for Nabiximols; Karyopharm's Xpovio; Kiadis USD 358M Buyout Visit Post
125 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
126 Bayer eyes AskBio’s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic Visit Post
127 GSK's RSV vaccine; SparingVision's interest in gene therapy; InCarda's raise; BridgeBio's R&D deal Visit Post
128 Venclexta full approval; PBP1510 Orphan Status; Roche/ Genesis collab; Immunomodulators for COVID-19 Visit Post
129 Cyclerion's olinciguat flunks sickle cell test; Nimbus nets $60M; Dyno-Roche's gene therapy pact; RayzeBio debuts with $ 45M to target tumors Visit Post
130 US/AZ deal; Alkermes' Schizophrenia drug; Innovent/Lilly's China market expansion; Rejection for Avenue Visit Post
131 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
132 MyoKardia buyout; Eidos acquisition; Amgen's Aimovig; HCV discovery; Bharat Biotech's Covaxin Visit Post
133 Brain's immune cells research update; Moderna's COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant's relugolix falls short in metastatic prostate cancer; Alnylam's lumasiran phase 3 result Visit Post
134 J&J 's COVID-19 vaccine; Roche, AC Immune's anti-Tau Alzheimer's drug; Silverback nets $85 M; Anokion's deal rides out BMS-Celgene merger; Coronavirus spike protein could inspire vaccine development Visit Post
135 Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome's Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks Visit Post
136 Lilly's COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian's CD40L cell therapy Visit Post
137 While AZ resumes its COVID-19 vaccine trial in the UK; Merck and Gilead are busy making sizeable Breast cancer deals Visit Post
138 Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates Visit Post
139 Amylyx's neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership Visit Post
140 Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK's COVID-19 monoclonal antibody therapy; AstraZeneca's Farxiga scores goal in Phase III CDK trial Visit Post
141 Moderna's COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates Visit Post
142 Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis Visit Post
143 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
144 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
145 FDA's Ok to Roche's Oral SMA Therapy; Roche's Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem Visit Post
146 Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV's peanut allergy patch; Combating COVID-19 with decoy target Visit Post
147 MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic's IMU-838 promising results Visit Post
148 Roche-UCB's $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures Visit Post
149 AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid's DMD gene therapy trial Visit Post
150 Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai's Collaboration; A new study on averting heart attack Visit Post
151 AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership Visit Post
152 Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update Visit Post
153 Merck, Dewpoint's HIV Pipeline; Pfizer, BioNTech 's COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer Visit Post
154 Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates Visit Post
155 Regeneron's cocktail antibody, REGN-COV2; J&J's manufacturing-spree; ObsEva's Yselty top-line studies Visit Post
156 Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Updates; Researchers Develop a New Ultrafast Insulin Visit Post
157 FDA’s No to Intercept’s NASH Drug; Roche’s Phesgo gets approval; Gilead’s Remdesivir pricing Visit Post
158 Regeneron's I-O Drug; Gene Therapy for Parkinson's Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M Visit Post
159 Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114's Phase III result Visit Post
160 Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab's result; Orca raises $192M Visit Post
161 HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results Visit Post
162 AbbVie & Genmab’s Collaboration; Lilly's antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent; Visit Post
163 Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL Visit Post
164 Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M; Visit Post
165 Eli Lilly's COVID-19 Antibody trial; Approval for Oriahnn; Gilead's Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19 Visit Post
166 Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost Visit Post
167 Algernon's NP-120; FDA nod to 4DMedical tool; SaNOtize's NORSTM trial; Pole's capital increase Visit Post
168 CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice Visit Post
169 Moderna's COVID-19 Vaccine; Quidel's Lyra gets EUA from FDA; Neurotrope and Metuchen Pharma Announced Merger Agreement; FDA Approval to Rucaparib; Visit Post
170 Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ's anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost Visit Post
171 Mavacamten Phase III clinical trial, FDA nod for Ovarian cancer therapy, Dyno Therapeutics & Novartis Collaboration, Abbott's COVID-19 diagnostic kit Visit Post
172 Avrobio taps Magenta’s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight pandemic, Visit Post
173 Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial Visit Post
174 Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials Visit Post
175 In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up Visit Post
176 AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes Visit Post
177 COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market Visit Post
178 Vir's drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines Visit Post
179 In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit Visit Post
180 AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure Visit Post
181 Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19 Visit Post
182 Niacin fights Glioblastoma, iTeos nets $125M, Pandion reels in $80M, Brii, Chinese partner, FDA to speed up COVID-19 therapies Visit Post
183 J&J's COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott's POC test; Cobra Bio raises $ 3.3 M Visit Post
184 FDA permits COVID-19 treatment, Roche's antibiotics pact, Moderna's vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million Visit Post
185 Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid Visit Post
186 Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial Visit Post
187 Moderna’s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib Visit Post
188 JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19 Visit Post
189 Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment Visit Post
190 CAR-T in killing tumors; Amunix raises $73M; Autism findings in protein-targeted treatment Visit Post
191 Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine Visit Post
192 US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing Visit Post
193 Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust Visit Post
194 J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug Visit Post
195 Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma Visit Post
196 Immune cells for age-related diseases; Regeneron's antibody for 2019-nCoV; FDA nods for hydrogel injection Visit Post
197 First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed's shares Soares Visit Post
198 Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey Visit Post
199 Acceleron Pharma's drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson's disease Visit Post
200 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
201 Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102 Visit Post
202 Thumbs down to NKTR-181, Lilly expands its insulin armamentarium Visit Post
203 Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug Visit Post
204 Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M Visit Post
205 Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO Visit Post
206 Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy Visit Post
207 GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3 Visit Post
208 Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval Visit Post
209 Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition Visit Post
210 Acquisition of ArQule; Synthorx; and Zentalis nabs a raise Visit Post
211 Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter Visit Post
212 Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients Visit Post
213 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
214 GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion Visit Post
215 Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod Visit Post
216 AbbVie Sells bonds to Fund Allergan takeover Visit Post
217 FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit Visit Post
218 Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences Visit Post
219 AstraZeneca tops the first Pharma Invention Index; Amgen to buy 20.5% stake in a Chinese pharmaceutical, BeiGene; Ascentage, Henlius collaborates to develop a Combination therapy Visit Post
220 AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood Visit Post
221 AZ announces positive results for durvalumab and tremelimumab; FDA nods to extend LILETTA’s use to prevent pregnancy; Gilead, Glympse Bio teams up to advance NASH clinical development Visit Post
222 Rapt Therapeutics files IPO; Novartis stakes $80M for NASH Visit Post
223 FDA approval to AZ’s Farxiga for heart failure; GSK divests two travel vaccines to Bavarian Nordic; New breakthrough therapy for Cystic Fibrosis Visit Post
224 EicOsis receives USD 15M to fuel its non-opioid pain therapy; Alexion Pharmaceuticals buys Achillion Pharmaceuticals; Ipsen adds another drug to its rare disease pipeline Visit Post
225 ImaginAb joins hands with AstraZeneca, Pfizer, Takeda Visit Post
226 AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara Visit Post
227 Roche’s Tecentriq combo proves effective in Bladder cancer Visit Post
228 STipe raises USD 22M; FDA approves Darzalex for multiple myeloma Visit Post
229 EU’s labels Nirogacestat an Orphan drug; FDA Approves First Smallpox, Monkeypox Vaccine; Evotec and Takeda collaborates to discover clinical candidates Visit Post
230 Flagship Pioneering launches Omega Therapeutics; EU nod to Vitrakvi; Bluebird Bio reveals positive results of Starbeam clinical trial Visit Post
231 Boehringer Ingelheim ties up with Inflammasome Therapeutics Visit Post
232 Fujifilm acquires global rights to Cynata's novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop's digital diabetes platform Visit Post
233 AlivaMab collaborates with Janssen for antibody discovery; Lundbeck acquires Alder BioPharmaceutical; Helsinn and Mundipharma announce China approval of Akynzeo Visit Post
234 Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership  Visit Post
235 Daiichi Sankyo fuels commercialization of DS-8201 in Japan; Roivant Sciences transfers its biotech stake for USD 3 Billion; FDA, EMA accepts marketing of Allergan’s abicipar Visit Post
236 Vertex acquires Semma; Luxturna gets approval for rare eye disorder Visit Post
237 Helsinn out licenses Pracinostat in South America Visit Post
238 HiFiBio raises USD 67 M; FDA drafts new guidelines for Breast cancer trials; Harbour BioMed teams up with Pharmaceutical Product Development Visit Post
239 Zogenix acquires Modis Therapeutics; Amgen buys Otezla; CRISPR slows down the Breast cancer rate Visit Post
240 Themis Bioscience collaborates with Merck; Oncorus raises USD 80 M; GSK files for Japanese approval of anaemia drug Visit Post
241 Juvenescence nets USD 100M; Sarepta DMD drug faces rejection Visit Post
242 EU approval for Imbruvica; Pharming licenses orphan drug Visit Post
243 GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn; Jazz Pharmaceuticals acquires Cavion; Ascletis opens a new Shanghai clinical research centre Visit Post
244 NMPA approves ALS treatment Edavarone; GSK ends development of Ebola vaccines; Vesselon Acquires FDA-Approved Imagent Visit Post
245 Turalio gets FDA approval; Sosei Heptares, Takeda forms an R&D pact Visit Post
246 FDA approval for Nubeqa; Biodesix, Immodulon collaborates on Cancer treatment; Cancer asset rights to Alligator Bioscience Visit Post
247 CHPM’s positive approval for 13 Medicines; NICE approval for AstraZeneca’s Olaparib; Exact Sciences to buy Genomic Health Visit Post
248 Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M; FDA approval for Ruxience for leukaemia Visit Post
249 FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia Visit Post
250 PureHealth acquires LYT-100; Sosei raises USD 2.5 M Visit Post
251 Recursion Pharmaceuticals nets USD 121M; Bayer's MRI agent gets a nod Visit Post
252 Osivax raises USD 9M; Smyraf launched; Revolution secures USD 100M Visit Post
253 NICE endorsement for Pfizer’s Vizimpro; Eisai, Dundee targets Cancer; Capital raise for AgaMatrix Visit Post
254 EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline Visit Post
255 FDA's approval to Pfizer’s Zirabev; Launch of Century Therapeutics; Imbruvica's recommendation from CHMP Visit Post
256 Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS; AbbVie buys Allergan Visit Post
257 Zejula's priority review; Erytech Pharma's new facility; good news for Krystal Visit Post
258 The Business Cocktail Visit Post
259 Notizia Visit Post
260 Telegenomics nets $23M; Merck acquires Tilos; ADC nabs; Sobi buys Novoimmune's assets Visit Post
261 Notizia Visit Post
262 The Business Cocktail Visit Post
263 Notizia Visit Post
264 The Business Cocktail Visit Post
265 Notizia Visit Post
266 The Business Cocktail Visit Post
267 Notizia Visit Post
268 Ginkgo to buy mining platform; Vertex, Kymera collaborate; ArcherDX nets $60M; Bayer to invest $150M Visit Post
269 Notizia Visit Post
270 AstraZeneca-Daiichi’s results; Novartis remunerates; Pfizer to acquire Therachon; Gilead & Goldfinch Bio collaboration Visit Post
271 Notizia Visit Post
272 The Business Cocktail Visit Post
273 Notizia Visit Post
274 GSK to spend $100M; Lilly sell; Sherlock Bio raises $31M; Deerfield, UIC to foster research Visit Post
275 Notizia Visit Post
276 Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal Visit Post
277 Notizia Visit Post
278 Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion Visit Post
279 Notizia Visit Post
280 AgomAb Therapeutics raises $23.5M; Allergan's eye drug; Good news for the patients; Dyne Therapeutics comes to life Visit Post
281 Notizia Visit Post
282 The Business Cocktail Visit Post
283 Notizia Visit Post
284 The Business Cocktail Visit Post
285 Approach for Cystic Fibrosis; An alternative for Statins; Oral medications not safe; Carbon monoxide poisoning treatment gets approval Visit Post
286 BioNTech lines up $800M; Deerfield remunerates; Britain's Smith & Nephew to acquire Osiris Visit Post
287 Notizia Visit Post
288 Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering Visit Post
289 ColdZyme inactivates viruses; Med for rare genetic disease; Common oral bacteria accelerate Colon cancer; CEPI and CureVac to develop an mRNA vaccine; Celastrol’s effectiveness Visit Post
290 The Business Cocktail Visit Post
291 Notizia Visit Post
292 Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M Visit Post
293 Notizia Visit Post
294 Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets Visit Post
295 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
296 Genentech remunerates Xencor; XPrize upraises fund; GSK gambles Visit Post
297 Notizia Visit Post
298 Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal Visit Post
299 Biodesix collaborates with MRM; Avoiding flu with an antibody; Soliris clears trial Visit Post
300 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
301 Notizia Visit Post
302 Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raises Visit Post
303 Notizia Visit Post
304 Apollomics raises; Pear Therapeutics raises $64M; Lilly to acquire Loxo Visit Post
305 Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod Visit Post
306 Atlas Venture raises; Harpoon files IPO; Boston Scientific bags Millipede Visit Post
307 Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA Visit Post
308 Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal Visit Post
309 HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer’s; Bristol-Myers, H3 Biomedicine discover RNA splicing Visit Post
310 Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M Visit Post
311 Notizia Visit Post
312 Roche signs Icagen; UCB devote $255M; Siemens Healthineers celebrates Visit Post
313 Notizia Visit Post
314 Prometic bags $50M; Vedanta receives $12M; Humira biosimilar deal Visit Post
315 Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates Visit Post
316 Notizia Visit Post
317 Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal Visit Post
318 Notizia Visit Post
319 Triple Negative Breast Cancer Visit Post
320 Gordon and Betty Moore Foundation gives $85M; Omeicos raises; Sanofi signs deal; Lilly grabs Visit Post
321 Cholera vaccine delivered; Rice-inspired breakthroughs; International partnerships Visit Post
322 FDA approves Zulresso; Pfizer receives approval; Novartis relinquishes Rituxan Visit Post
323 Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO Visit Post
324 Notizia Visit Post
325 Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives Visit Post
326 Notizia Visit Post
327 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
328 Notizia Visit Post
329 COMMERCIAL AND OTHERS Visit Post
330 KEY CLINICAL OUTCOMES Visit Post
331 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
332 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
333 Notizia Visit Post
334 Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner Visit Post
335 Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune Visit Post
336 Notizia Visit Post
337 Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research Visit Post
338 Notizia Visit Post
339 Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M Visit Post
340 Notizia Visit Post
341 4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker Visit Post
342 Notizia Visit Post
343 Commercial Visit Post
344 Clinical Visit Post
345 AbbVie Receives Approval; Kymriah Approved; Shire Gets USFDA Approval; NICE Rejects; Bristol-Myers Squibb’s Opdivo; Eisai and Merck Get USFDA Approval Visit Post
346 Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts Visit Post
347 Notizia Visit Post
348 AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal Visit Post
349 Kalydeco got approved; Opdivo for SCLC; FDA approved for pain relief; GC4419 obviates Visit Post
350 KEY CLINICAL OUTCOMES Visit Post
351 Regulatory Visit Post
352 Commercial Visit Post
353 The Business Cocktail(Therapeutics) Visit Post
354 Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup Visit Post
355 Progenics got FDA Approval; Curcumin to cancer cells Visit Post
356 Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration Visit Post
357 Business Cocktail Visit Post
358 Commercial Outcomes - Novartis Visit Post
359 Key Clinical Outcomes- 30/07/2018 Visit Post
360 Neuroscience Highlights - 17/07/2018 Visit Post
361 Oncology Highlights - 30/07/2018 Visit Post
362 Notizia Visit Post
363 Idera's drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates Visit Post
364 Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation Visit Post
365 Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating Visit Post
366 Business Cocktail Visit Post
367 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
368 Horizon Discovery declines Abcam’s USD 367 million takeover bid Visit Post
369 Notizia Visit Post
370 Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients Visit Post
371 Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs Visit Post
372 Business Cocktail Visit Post
373 Business Cocktail Visit Post
374 Notizia Visit Post
375 Business Cocktail Visit Post
376 Notizia Visit Post
377 NOTIZIA Visit Post
378 The Business Cocktail : Latest Pharma deals Visit Post
379 CRISPR to cure sickle cell; FDA rejected; Stem cells use; Celgene spinoff Visit Post
380 Symdeko’s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers Visit Post
381 Business Cocktail Visit Post
382 Notizia Visit Post
383 Business Cocktail Visit Post
384 Notizia Visit Post
385 Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon Visit Post
386 Notizia Visit Post
387 Adapsyn signed; Evolus filed; BioNTech signed a deal; Nordisk’s deal Visit Post
388 Notizia Visit Post
389 Business Cocktail Visit Post
390 NOTIZIA Visit Post
391 Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln's anti-malarial drug Visit Post
392 Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allergan on women’s health Visit Post
393 December 7 Business Cocktail Visit Post
394 KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s Repatha Visit Post
395 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
396 EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opioid lawsuit Visit Post
397 Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires Visit Post
398 Business Cocktail Visit Post
399 Teva sells generics; Valeant trades; Roche's Genentech; J&J's next potential frontier Visit Post
400 AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes Visit Post
401 Novo petitions FDA;J&J invests; Xarelto’s trial; Roche's Tecentriq Visit Post
402 C-X-C Chemokine Receptor Inhibitors–The Emerging Therapeutic Agents Visit Post
403 Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal Visit Post
404 Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval Visit Post
405 Business Cocktail Visit Post
406 Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for the treatment of COPD Visit Post
407 Business cocktail Visit Post
408 Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval Visit Post
409 CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M Visit Post
410 Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults Visit Post
411 Business CockTail Visit Post
412 Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant Visit Post
413 Cannabidiol trial; MyoKardia aims; LDL drug data Visit Post
414 Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter Visit Post
415 Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project Visit Post
416 Takeda scores; PhRMA launches; Valeant's Obagi; Ex-Novo executive signs Visit Post
417 Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent gets struck down Visit Post
418 Stada’s €5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clementia files for $115M IPO Visit Post
419 Merck got attack; Stada's €5.32B; Private equity fund buys; Lonza on $5.5B deal Visit Post
420 Takeda knocks Velcade; FDA nod awaited; Novartis gets approval; Astellas UK dodges; Haegarda set for launch Visit Post
421 Novartis on AMD drug; Hospira recall of vials; Takeda wraps up; FDA bans imports Visit Post
422 J&J nabs; Clovis plots Rubraca; Novartis scores EU approval; Seattle Genetics stops trials Visit Post
423 Sanofi invests; ICER pitches; $6M in NIH; Pfizer, Roche cancer drug pricing Visit Post
424 Invokana matches; Xultophy beats; Lilly and BI follow; Tresiba matches Visit Post
425 AZ offloads; Pfizer's deal; Takeda’s work on plant; Germany's doc payment Visit Post
426 Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins; Alecensa trounces Visit Post
427 Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal Visit Post
428 Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics expands Visit Post
429 Merck's Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women's health Visit Post
430 AZ’s benralizumab; Sanofi, Regeneron set; Nordisk preps; European countries offer Visit Post
431 Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J's Invokana Visit Post
432 Novartis, slammed by Korean scandal; FDA tweaks; Dendreon eyes; Amgen adds Visit Post
433 Valeant's $50M; Sanofi vows; Top pharmas team up; PhRMA expels Visit Post
434 Lilly moves ahead; Authorities raid; Bristol-Myers, AZ in legal; PhRMA expected to weed out Visit Post
435 Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal Visit Post
436 FDA Approves; AZ nabs; Nordisk settles; Novartis pays Visit Post
437 Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A Visit Post
438 Samsung biosim nod sets; Lilly's med hits; BioMarin sees pricing; Spinraza scores; Klick creates Visit Post
439 Drug shortage; Fujifilm invests; Cobra Biologics to pump $19M; The world's most pricey drugs Visit Post
440 Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill Visit Post
441 Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B; Fresenius in buyout talks Visit Post
442 Dengvaxia study; Opdivo racks up; FDA issues plant; Teva's Rimsa fraud; Mission bags Fox grant Visit Post
443 Valeant's asset-sale; Sanofi coughs up $19.8M; Sanofi's Genzyme; India's Alkem; GSK’s inhalers Visit Post
444 Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall Visit Post
445 Mylan closing Illinois plant; Insys spends $24M; Roche's Ocrevus; Greece’s corruption prosecutor quits Visit Post
446 Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings Visit Post
447 Letter for AstraZeneca; Patheon on API plant; Sanofi, Regeneron’s Dupixent; Cerulean Pharma and Daré Bioscience enter into deal; Lilly on price hikes Visit Post
448 Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns Visit Post
449 GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss Visit Post
450 Pfizer faces patent loss; Allergan over generics probe; Sun Pharma rallies Visit Post
451 Business Cocktail Visit Post
452 NPPA slams; Japan Joins Trump; PCI Pharma Announces Expansion; Merck opens plant; Mylan and Biocon win Visit Post
453 Clinigen and Eisai team up; Sanofi, Lonza enter; Fidia to acquire; J&J completes acquisition Visit Post
454 Prosecutors rope Pfizer; Pharma groups to FDA; Regeneron simulates; Otsuka & Lundbeck revive;Philidor execs plead Visit Post
455 PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch Visit Post
456 USFDA warns; Vit B3 prevents glaucoma; Zydus Cadila receives nod; U.S. experts soften on DNA editing Visit Post
457 Reckitt Acquired Mead Johnson; LabCorp’s acquisition; Ferring collaborates; J&J Licenses Visit Post
458 SEC scrutinizes; Acacia meets endpoint; Axovant's dementia drug; Novartis expands; Aurobindo responds Visit Post
459 AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires; Renova takes over Rights Visit Post
460 FDA approves; Sun Pharma Recalls; Mezzion filed; Sanofi’s antibody to treat Visit Post
461 ALCMI, ALCF and Scancell partner; Sun unloads Ohm Labs plants; Takeda and Ovid join; Guardant and MD Anderson collaborate; Glooko and Ascensia integrate Visit Post
462 AstraZeneca announces; Trivitron launches; BrainStorm Cell Therapeutics validates Visit Post
463 Payers block EpiPen; Allergan charged; AbbVie's Humira; Baxter paying $18M Visit Post
464 U.K. weighs drug rationing; Applying Digital; FDA slaps Florida Visit Post
465 Astellas ditches UMN Pharma; J&J, Actelion land on a price; Bayer’s pledge; Biogen to fork over $1.25B-plus Visit Post
466 FDA accepts; Keytruda takes lead; M Pharmaceutical develops; Merck Deploys Palantir Visit Post
467 Aurobindo takes top generic spot; Valeant unloads Dendreon; Ipsen strikes $1B deal; Takeda shells out $5.2B Visit Post
468 Sanofi, Regeneron one step closer; Pharma's deal; J&J and Actelion deal Visit Post
469 Sanofi sues Novo; Allergan gets help; Actelion snubs; Impax CEO Wilkinson out Visit Post
470 Pfizer uses; FDA approves; EMA approves; Mylan launches Visit Post
471 CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective Visit Post
472 Novartis joins; Sanofi weighs Actelion; Valeant and Takeda's $10B deal; Astellas scouts pipeline Visit Post
473 Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat Visit Post
474 EC grants; Pfizer cuts; 27 medicines sold; Keytruda nabs Visit Post
475 Novartis Buys; FDA approves; Mayne Pharma Launches; Oxford Genetics Receives Grant Visit Post
476 Novartis eyes; Pfizer considers cashing; Mylan pushes to seal $465M; Valeant with Takeda for deal Visit Post
477 Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika Visit Post
478 Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration; UPS to Acquire Marken Visit Post
479 Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan's MAA accepted; Pricing hit pharma Visit Post
480 Sun Pharma Announces Launch; OptiNose files; Opiant obtains rights; Swissmedic approves Visit Post
481 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
482 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
483 Merck launches Biosimilars, ABITEC announces extension, First human clinical trial, FDA awards 2grants, Corden Pharma Expands, Juniper Pharma Services Offers Visit Post
484 Bayer Partners with DelSiTech to Develop; Amgen and Arrowhead Announce; Allergan, AstraZeneca’s deal; Lexicon Pharma announces deal Visit Post
485 FDA Approves STELARA; Novartis announces AMG 334; AbbVie's HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction Visit Post
486 Bayer AG & Evotec AG’s deal; Plasticell and CellSpring AG’s deal; Allergan Acquires Akarna; Cambrex Acquires Pharmacore Visit Post
487 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
488 Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Visit Post
489 Piramal buys; Abbott Buys Glomed; Merck Divesting; Takeda set to sell; Teva gets clearance Visit Post
490 Roche's drug; Cancer drugs risk; FDA norms; Takeda sets deal Visit Post
491 Sun Pharma forms partnership; Pfizer and DCRI collaborate; Avara Acquires AZ; ASLAN Pharmaceutical’s Collaboration; Amgen and Servier partnership Visit Post
492 Treatment for esophageal cancer; FDA bans soaps; Dr Reddy's Launches; Cipla Gets Approval Visit Post
493 Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug Visit Post
494 NATCO Pharma surges; AstraZeneca falls; US patent office rules Visit Post
495 Bristol Meyers Squibb & AbbVie partner; BioLineRx’s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer Visit Post
496 Business Cocktail Visit Post
497 Lupin acquired; FDA grants approval; NATCO gets approval; Wockhardt Ltd. gets import alert; Patent fight Visit Post
498 Notizia Visit Post
499 The Business Cocktail Visit Post
500 Rising of Orphan Drug Development Visit Post